Citizens JMP Reiterates Market Outperform Rating on Altimmune (ALT)

March 14, 2025 4:06 AM EDT Send to a Friend
Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $25.00 price target on Altimmune (NASDAQ: ALT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login